ASCO GUIDELINES Bundle

Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475441

Contents of this Issue

Navigation

Page 5 of 7

Antimicrobial Prophylaxis Table 2. Summary of Recommendations for Antimicrobial Prophylaxis Type of prophylaxis Population Recommendations Timing of prophylaxis Antibacterial Patients at high risk of febrile neutropenia (Table 1) or profound, protracted neutropenia Fluoroquinolone prophylaxis is recommended. During period of expected neutropenia. Antifungal Patients at high risk of febrile neutropenia (Table 1) or profound, protracted neutropenia Patients with gra versus host disease (GVHD) Oral triazole or parenteral echinocandin prophylaxis is recommended; a mold-active triazole is recommended where the risk of invasive aspergillosis is >6%, such as in patients with AML/MDS, or during treatment of GVHD. During period of expected neutropenia. Patients receiving chemotherapy regimens associated with >3.5% risk for pneumonia from Pneumocystis jirovecii (e.g. those with ≥20 mg prednisone equivalents daily for ≥1 month or those based on purine analogs) Prophylaxis is recommended. Post-myeloid reconstitution or engrament aer SCT, particularly in the setting of post- engrament augmented immunosuppression (for the treatment of GVHD). Antiviral HSV-seropositive patients undergoing HSCT or leukemia induction therapy Antiviral prophylaxis with a nucleoside analog is recommended (e.g. acyclovir). Until recovery of the white blood cell count or resolution of mucositis, whichever occurs later. Duration can be extended for persons with frequent recurrent HSV infections or those with GVHD or can be continued as VZV prophylaxis for up to one year.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression